Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-05-28Clinical Trial Update: PHA-739358 for Treatment of Hormone Refractory Prostate Cancer [Phase 2]
Phase 2 clinical trial update of PHA-739358 in metastatic castration-resistant prostate cancer; study completed.
-
CLINICAL_TRIALS trial_result · 2014-05-26Clinical Trial Update: A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer [Phase 1]
A Phase 1 study of CNTO 328 (siltuximab) in patients with metastatic hormone-refractory prostate cancer has completed.
-
FDA approval · 2014-05-13FDA Approved: ZYTIGA — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for ZYTIGA (abiraterone acetate) submitted by Janssen Biotech, Inc.
-
CLINICAL_TRIALS trial_result · 2014-05-07Clinical Trial Update: A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases [Phase 3]
Phase III trial evaluating Radium-223 dichloride in symptomatic hormone-refractory prostate cancer with skeletal metastases completed; resul…
-
CLINICAL_TRIALS trial_result · 2014-04-30Clinical Trial Update: A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 trial assessing the short-term safety of continuous dosing of abiraterone acetate with prednisone under modified fasting and fed sta…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-04-23Clinical Trial Update: Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy [Phase 1]
Phase 1 safety study of repeated dosing with a cytotoxic lymphocyte–based therapy for hormone-refractory prostate cancer, with results poste…
-
FDA approval · 2014-04-17FDA Approved: ZYTIGA — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for ZYTIGA (abiraterone acetate) from Janssen Biotech, Inc.
-
CLINICAL_TRIALS trial_result · 2014-04-07Clinical Trial Update: Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients [Phase 2]
A Phase 2 study evaluating single-agent temsirolimus (Torisel) in chemotherapy-naïve castration-resistant prostate cancer; results were post…
-
CLINICAL_TRIALS trial_result · 2014-04-07Clinical Trial Update: Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer [Phase 1, Phase 2]
Phase 1/2 trial evaluating sorafenib to overcome resistance to systemic chemotherapy in androgen-independent (castration-resistant) prostate…
-
FDA approval · 2014-04-01FDA Approved: ZYTIGA — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ZYTIGA (abiraterone acetate) from Janssen Biotech, Inc., resulting in a label modification/expan…
-
CLINICAL_TRIALS withdrawal · 2014-03-24Clinical Trial Update: Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients [Phase 1, Phase 2]
Phase I/II trial of ASP9521 in castration-resistant prostate cancer has been terminated.
-
CLINICAL_TRIALS trial_result · 2014-03-10Clinical Trial Update: AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer [Phase 1, Phase 2]
This entry reports the completion of a Phase 1/2 clinical trial evaluating AMG 102 in combination with mitoxantrone and prednisone in men wi…
-
CLINICAL_TRIALS trial_result · 2014-03-03Clinical Trial Update: The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer [Phase 1, Phase 2]
A Phase 1/2 study evaluated the combination of everolimus (RAD001) with docetaxel in metastatic castration-resistant prostate cancer; the tr…
-
CLINICAL_TRIALS withdrawal · 2014-02-19Clinical Trial Update: Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer [Phase 2]
A Phase 2 study of G-202 for chemotherapy-naïve metastatic castration-resistant prostate cancer has been withdrawn.
-
FDA approval · 2014-02-07FDA Approved: ZYTIGA — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ZYTIGA (abiraterone acetate) from Janssen Biotech, Inc.
-
CLINICAL_TRIALS trial_result · 2014-02-06Clinical Trial Update: Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer [Phase 3]
Phase 3 randomized trial comparing docetaxel plus dasatinib vs docetaxel plus placebo in castration-resistant prostate cancer; results were …
-
CLINICAL_TRIALS trial_result · 2014-01-08Clinical Trial Update: A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer [Phase 2]
The document reports a Phase 2 safety study of ZD4054 (zibotentan) in patients with metastatic hormone-resistant prostate cancer; the trial …
-
CLINICAL_TRIALS trial_result · 2013-12-24Clinical Trial Update: Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer [Phase 2]
This phase 2 trial compared continuing docetaxel versus switching to cabazitaxel after a minor PSA response in metastatic castration-resista…
-
CLINICAL_TRIALS trial_result · 2013-12-11Clinical Trial Update: Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer [Phase 2]
A Phase 2 clinical trial evaluating the combination of oxaliplatin and pemetrexed disodium in patients with refractory hormone-resistant pro…
-
CLINICAL_TRIALS trial_result · 2013-12-05Clinical Trial Update: Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC) [Phase 2]
Clinical Trial Update reporting a Phase II study of Hamsa-1 in metastatic castration-resistant prostate cancer, sponsored by Tiltan Pharma L…
-
CLINICAL_TRIALS trial_result · 2013-12-04Clinical Trial Update: Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001
Clinical trial update reporting molecular, genetic, and genomic assessments from patients with metastatic castration-resistant prostate canc…
-
CLINICAL_TRIALS trial_result · 2013-11-27Clinical Trial Update: Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer [Phase 1, Phase 2]
A Phase 1/2 trial evaluated dasatinib in combination with docetaxel for metastatic hormone-refractory prostate cancer; results were posted i…
-
CLINICAL_TRIALS trial_result · 2013-10-17Clinical Trial Update: Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer [Phase 2]
This update reports the results of a Phase 2 trial of erlotinib as a single agent in chemotherapy-naive androgen-independent (castration-res…
-
CLINICAL_TRIALS withdrawal · 2013-10-16Clinical Trial Update: Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer [Phase 2]
A Phase 2 trial evaluating cabazitaxel in men aged 75 years or older with metastatic castration-resistant prostate cancer has been withdrawn…
-
CLINICAL_TRIALS trial_result · 2013-10-10Clinical Trial Update: Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer [Phase 3]
A Phase 3 trial evaluating aflibercept in combination with docetaxel for metastatic castration-resistant prostate cancer has completed with …